SCHEMBL5688665

SCHEMBL5688665

Cc1cccc(CCc2ccc(OC(=O)N3CCC(On4ccnc4)CC3)cc2)n1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.40
FAAH O00519 3/20 0.37
GAA P10253 1/20 0.36
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
NPY2R P49146 3/20 0.33
KCNH2 Q12809 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
KDM4E B2RXH2 2/20 0.33
POLB P06746 1/20 0.33
MGLL Q99685 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5690492 0.92 KMT2A (0.40) KMT2AFAAHGAANPC1RAB9A
SCHEMBL5690565 0.88 GRIN2B (0.37) KMT2AFAAHGAANPC1RAB9A
SCHEMBL5688265 0.86 KMT2A (0.41) KMT2AGAANPC1RAB9ANPY2R
SCHEMBL5691076 0.84 NOS1 (0.38) FAAHGAANPC1RAB9ANPY2R
SCHEMBL5689981 0.84 AOC3 (0.39) FAAHGAACYP2C19
SCHEMBL5689283 0.82 FAAH (0.37) KMT2AFAAHGAANPC1RAB9A
SCHEMBL5690784 0.80 FAAH (0.39) FAAHGAANPC1RAB9ANPY2R
SCHEMBL5689252 0.80 GRIN2B (0.38) KMT2AGAANPC1RAB9AMGLL
SCHEMBL5688495 0.79 KMT2A (0.49) KMT2AGAANPC1RAB9AKCNH2
SCHEMBL5687849 0.79 KMT2A (0.54) KMT2AGAANPC1RAB9AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160851-A1 Substituted piperidine carbamates LIPE, PNLIP, LIPC KMT2A 1520/4885FAAH 160/4885GAA 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.